Targapremir-210-TGP-210-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemETargapremir-210Cat.No.:HY-15861CASNo.:1049722-30-6Synonyms:TGP-210分⼦式:C₃₂H₃₆N₁₀O₂分⼦量:592.69作⽤靶点:MicroRNA;Apoptosis作⽤通路:Epigenetics;Apoptosis储存⽅式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性数据体外实验DMSO:250mg/mL(421.81mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制备储备液1mM1.6872mL8.4361mL16.8722mL5mM0.3374mL1.6872mL3.3744mL10mM0.1687mL0.8436mL1.6872mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存⽅式和期限：-80°C,6months;-20°C,1month。-80°C储存时，请在6个⽉内使⽤，-20°C储存时，请在1个⽉内使⽤。体内实验请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照InVitro⽅式配制澄的储备液，再依次添加助溶剂：(为保证实验结果的可靠性，澄的储备液可以根据储存条件，适当保存；体内实验的⼯作液，建议您现⽤现配，当天使⽤；以下溶剂前显⽰的百分⽐指该溶剂在您配制终溶液中的体积占⽐；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的⽅式助溶)1.请依序添加每种溶剂：10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/2MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemESolubility:≥2.08mg/mL(3.51mM);Clearsolution2.请依序添加每种溶剂：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.08mg/mL(3.51mM);ClearsolutionBIOLOGICALACTIVITY⽣物活性Targapremir-210(TGP-210)⼀种有效的、选择性的miR-210(miRNA-210,microRNA-210)抑制剂。Targapremir-210以⾼亲和⼒抑制pre-miR-210的加⼯(Kd~200nM)[1]。IC50&TargetIC50:200nM(miR-210,inMDA-MB-231cells)[1].体外研究Targapremir-210decreasesmaturemiR-210levelsinMDA-MB-231cellsculturedunderhypoxicconditions,withanIC50of-200nM[1].Targapremir-210(200nM)inducesMDA-MB-231cellsapoptosisisselectiveforthehypoxicenvironment.Targapremir-210inducescellsapoptosisunderhypoxicconditionsanddoesnotinduceapoptosisinMDA-MB-231cellsculturedinnormoxia[1].体内研究Targapremir-210(100μLof200nM;singlei.p.injection)impedesMDA-MB-231triplenegativebreastcancer(TNBC)cellsproliferationinvivo.Targapremir-210isabletoreachthetumorandsustainfortheentire21-dayperiod,anddecreasestumorburdeninaTNBCmousemodel[1].AnimalModel:NOD/SCIDmiceweresubcutaneouslytransplantedcellsuspensionintobreastfatpads[1].Dosage:100μLof200nMAdministration:Singlei.p.injection24hpost-transplantationResult:Decreasedtumorgrowthasassessedbyluciferasesignalintensityandmassoftheresectedtumor.REFERENCES[1].CostalesMG,etal.SmallMoleculeInhibitionofmicroRNA-210ReprogramsanOncogenicHypoxicCircuit.JAmChemSoc.2017Mar8;139(9):3446-3455.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forr